| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $22,621,971 | 17 | 100 |
| McHugh Julie | director | 0 | $0 | 1 | $80,460 | $-80,460 |
| Martini Gregory S. | Chief Financial Officer | 0 | $0 | 2 | $81,888 | $-81,888 |
| Gaskins Tammi L | Chief Commercial Officer | 0 | $0 | 3 | $100,301 | $-100,301 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug | 0 | $0 | 2 | $121,586 | $-121,586 |
| John Minardo | Chief Legal Officer | 0 | $0 | 2 | $136,177 | $-136,177 |
| MCCOURT Thomas A | Chief Executive Officer | 0 | $0 | 2 | $739,929 | $-739,929 |
| Silver Ronald | Principal Accounting Officer | 0 | $0 | 4 | $831,182 | $-831,182 |
| DENNER ALEXANDER J | director | 0 | $0 | 1 | $20.53M | $-20.53M |
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European …
Over the last 12 months, insiders at Ironwood Pharmaceuticals, Inc. have bought $0 and sold $22.62M worth of Ironwood Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Ironwood Pharmaceuticals, Inc. have bought $230,269 and sold $8.45M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,920 shares for transaction amount of $60,204 was made by Duane Jon R (director) on 2024‑03‑06.
| 2026-07-07 | Sale | Silver Ronald | PFO & PAO | 127,890 0.0786% | $4.52 | $578,063 | -8.84% | |
| 2026-06-16 | Sale | McHugh Julie | director | 21,571 0.0134% | $3.73 | $80,460 | +11.48% | |
| 2026-03-17 | Sale | DENNER ALEXANDER J | director | 6.73M 3.8741% | $3.05 | $20.53M | +20.31% | |
| 2026-02-24 | Sale | MCCOURT Thomas A | Chief Executive Officer | 103,526 0.0615% | $3.66 | $378,905 | +1.85% | |
| 2026-02-24 | Sale | Shetzline Michael | SVP, CMO, Head-Res&Drug | 17,012 0.0101% | $3.66 | $62,264 | +1.85% | |
| 2026-02-24 | Sale | John Minardo | Chief Legal Officer | 19,053 0.0113% | $3.66 | $69,734 | +1.85% | |
| 2026-02-24 | Sale | Silver Ronald | Principal Accounting Officer | 12,621 0.0075% | $3.66 | $46,193 | +1.85% | |
| 2026-02-24 | Sale | Gaskins Tammi L | Chief Commercial Officer | 11,239 0.0067% | $3.66 | $41,135 | +1.85% | |
| 2026-02-24 | Sale | Martini Gregory S. | Chief Financial Officer | 11,457 0.0068% | $3.66 | $41,933 | +1.85% | |
| 2026-02-23 | Sale | MCCOURT Thomas A | Chief Executive Officer | 94,757 0.0592% | $3.81 | $361,024 | +2.80% | |
| 2026-02-23 | Sale | Shetzline Michael | SVP, CMO, Head-Res&Drug | 15,570 0.0097% | $3.81 | $59,322 | +2.80% | |
| 2026-02-23 | Sale | John Minardo | Chief Legal Officer | 17,439 0.0109% | $3.81 | $66,443 | +2.80% | |
| 2026-02-23 | Sale | Silver Ronald | Principal Accounting Officer | 11,552 0.0072% | $3.81 | $44,013 | +2.80% | |
| 2026-02-23 | Sale | Gaskins Tammi L | Chief Commercial Officer | 10,287 0.0064% | $3.81 | $39,193 | +2.80% | |
| 2026-02-23 | Sale | Martini Gregory S. | Chief Financial Officer | 10,487 0.0065% | $3.81 | $39,955 | +2.80% | |
| 2026-01-05 | Sale | Silver Ronald | Principal Accounting Officer | 35,416 0.0218% | $4.60 | $162,914 | -13.51% | |
| 2025-11-17 | Sale | Gaskins Tammi L | Chief Commercial Officer | 6,016 0.0039% | $3.32 | $19,973 | +23.32% | |
| 2025-08-11 | Sale | John Minardo | Chief Legal Officer | 7,754 0.0048% | $0.84 | $6,513 | +326.88% | |
| 2025-08-11 | Sale | Silver Ronald | Principal Accounting Officer | 2,846 0.0018% | $0.84 | $2,391 | +326.88% | |
| 2025-08-11 | Sale | Gaskins Tammi L | Chief Commercial Officer | 1,316 0.0008% | $0.84 | $1,105 | +326.88% |
| DENNER ALEXANDER J | director | 9188635 5.5608% | $32.16M | 8 | 1 | +18.72% |
| Ridgeback Capital Investments L.P. | 10 percent owner | 6842839 4.1412% | $23.95M | 3 | 42 | <0.0001% |
| Hecht Peter M | Chief Executive Officer | 4696917 2.8425% | $16.44M | 1 | 16 | +9.03% |
| Emany Sravan Kumar | SVP, COO and CFO | 309572 0.1873% | $1.08M | 2 | 2 | <0.0001% |
| Owens Edward P | director | 218954 0.1325% | $766,339.00 | 4 | 0 | +34.25% |
| Duane Jon R | director | 121028 0.0732% | $423,598.00 | 1 | 0 | <0.0001% |
| Fanucci Marsha | director | 19778 0.012% | $69,223.00 | 1 | 1 | <0.0001% |
$14,599,168 | 59 | 12.79% | $1.66B | |
$102,709,455 | 46 | 30.55% | $1.45B | |
$33,884,330 | 45 | 12.56% | $223.45M | |
$73,762,556 | 45 | -9.99% | $2.17B | |
$98,035,963 | 43 | -10.97% | $486.79M |
| Increased Positions | 121 | +71.6% | 19M | +12.67% |
| Decreased Positions | 68 | -40.24% | 13M | -8.57% |
| New Positions | 59 | New | 9M | New |
| Sold Out Positions | 20 | Sold Out | 7M | Sold Out |
| Total Postitions | 222 | +31.36% | 155M | +4.1% |
| Armistice Capital, Llc | $68,961.00 | 9.91% | 16.15M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $68,627.00 | 9.86% | 16.07M | -130,123 | -0.8% | 2025-09-30 |
| Sarissa Capital Management Lp | $67,976.00 | 9.77% | 15.92M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $51,507.00 | 7.4% | 12.06M | +39,560 | +0.33% | 2025-09-30 |
| Bank Of America Corp /De/ | $49,940.00 | 7.18% | 11.7M | +8M | +248.3% | 2025-09-30 |
| Renaissance Technologies Llc | $35,664.00 | 5.12% | 8.35M | -53,996 | -0.64% | 2025-09-30 |
| Acadian Asset Management Llc | $27,766.00 | 3.99% | 6.5M | -47,194 | -0.72% | 2025-09-30 |
| Kynam Capital Management, Lp | $23,343.00 | 3.35% | 5.47M | 0 | 0% | 2025-09-30 |
| Aqr Capital Management Llc | $22,966.00 | 3.3% | 5.38M | -787,102 | -12.77% | 2025-09-30 |
| Charles Schwab Investment Management Inc | $20,997.00 | 3.02% | 4.92M | +1M | +34.2% | 2025-09-30 |